[go: up one dir, main page]

MA29919B1 - Nouvelle utilisation de composes il-1beta - Google Patents

Nouvelle utilisation de composes il-1beta

Info

Publication number
MA29919B1
MA29919B1 MA30863A MA30863A MA29919B1 MA 29919 B1 MA29919 B1 MA 29919B1 MA 30863 A MA30863 A MA 30863A MA 30863 A MA30863 A MA 30863A MA 29919 B1 MA29919 B1 MA 29919B1
Authority
MA
Morocco
Prior art keywords
receptor
compounds
arthritis
ligand
prevention
Prior art date
Application number
MA30863A
Other languages
English (en)
Inventor
Phil Lowe
Hermann Gram
Thomas Jung
Timothy Wright
Trevor Mundel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29919(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29919B1 publication Critical patent/MA29919B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)

Abstract

LA PRÉSENTE A TRAIT À UNE NOUVELLE UTILISATION DE COMPOSÉS DE DISRUPTION DU RÉCEPTEUR IL-1ß-LIGAND/IL-1 (DÉSIGNÉS COMPOSÉS 'IL-1BÊTA), TELS QUE DES COMPOSÉS À BASE DE PETITES MOLÉCULES DE DISRUPTION D'INTERACTION DU RÉCEPTEUR IL-1ß-LIGAND/IL-1 D'ANTICORPS DU RÉCEPTEUR IL-1ß OU IL-1, PAR EXEMPLE, DES COMPOSÉS DE LIAISON À IL-1ß OU DES COMPOSÉS DE LIAISON AU RÉCEPTEUR IL-1, ET/OU DES COMPOSÉS À BASE D'ARN RÉDUISANT DES NIVEAUX DE PROTÉINES SOIT DE LIGANDS IL-1ß OU DU RÉCEPTEUR IL-1, DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE SYNDROMES AUTO-INFLAMMATOIRES, PAR EXEMPLE, LE SYNDROME DE L'ARTHRITE RHUMATOÏDE JUVÉNILE OU DE L'ARTHRITE RHUMATOÏDE DE L'ADULTE ET À DES PROCÉDÉS DE TRAITEMENT ET/OU DE PRÉVENTION DE SYNDROMES AUTO-INFLAMMATOIRES, PAR EXEMPLE, LE SYNDROME DE L'ARTHRITE RHUMATOÏDE JUVÉNILE OU DE L'ARTHRITE RHUMATOÏDE DE L'ADULTE, CHEZ DES MAMMIFÈRES, NOTAMMENT DES HUMAINS.
MA30863A 2005-10-26 2008-04-23 Nouvelle utilisation de composes il-1beta MA29919B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02

Publications (1)

Publication Number Publication Date
MA29919B1 true MA29919B1 (fr) 2008-11-03

Family

ID=37806690

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30863A MA29919B1 (fr) 2005-10-26 2008-04-23 Nouvelle utilisation de composes il-1beta

Country Status (28)

Country Link
US (8) US8105587B2 (fr)
EP (5) EP1940465B1 (fr)
JP (4) JP2009513645A (fr)
KR (3) KR101518064B1 (fr)
CN (2) CN101291693B (fr)
AU (1) AU2006306280B2 (fr)
BR (1) BRPI0617830B8 (fr)
CA (3) CA2963828A1 (fr)
CY (4) CY1113378T1 (fr)
DK (2) DK2848258T3 (fr)
ES (3) ES2662420T3 (fr)
HU (2) HUE036973T2 (fr)
IL (4) IL190545A (fr)
JO (2) JO2826B1 (fr)
LT (3) LT2848258T (fr)
LU (2) LU92326I2 (fr)
MA (1) MA29919B1 (fr)
NO (2) NO345888B1 (fr)
NZ (1) NZ567222A (fr)
PH (2) PH12013501287B1 (fr)
PL (2) PL1940465T3 (fr)
PT (2) PT1940465E (fr)
RU (2) RU2468817C2 (fr)
SI (2) SI1940465T1 (fr)
TN (1) TNSN08189A1 (fr)
TR (1) TR201802449T4 (fr)
TW (3) TWI626056B (fr)
WO (1) WO2007050607A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513645A (ja) * 2005-10-26 2009-04-02 ノバルティス アクチエンゲゼルシャフト ＩＬ−１β化合物の新規使用
AU2012203932B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
JP2010528086A (ja) 2007-05-29 2010-08-19 ノバルティス アーゲー 抗ｉｌ−１治療に関する新しい適応症
JP5607613B2 (ja) * 2008-06-06 2014-10-15 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 関節リウマチの治療のための方法
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
EP2477647B1 (fr) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation de produits d'immunothérapie à base de levure et réponses associées
BR112012007365A2 (pt) * 2009-10-15 2016-11-22 Abbott Lab proteínas de ligação à il-1
KR101848225B1 (ko) * 2010-05-14 2018-04-12 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
BR112013015944A2 (pt) * 2010-12-21 2018-06-19 Abbvie Inc imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
CN103649336A (zh) 2011-05-10 2014-03-19 雀巢产品技术援助有限公司 用于个体化治疗管理的疾病活动性表征方法
US11377656B2 (en) 2016-03-10 2022-07-05 Novartis Ag Chemically modified messenger RNA's
US11162943B2 (en) 2017-05-31 2021-11-02 Prometheus Biosciences Inc. Methods for assessing mucosal healing in Crohn's disease patients
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
JP2021523894A (ja) 2018-05-09 2021-09-09 ノバルティス アーゲー カナキヌマブの使用
CN113227137A (zh) * 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
CA3119582A1 (fr) 2018-12-21 2020-06-25 Novartis Ag Utilisation d'anticorps de liaison de il-1.beta.
WO2020128637A1 (fr) 2018-12-21 2020-06-25 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
TWI793503B (zh) 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
US20250099548A1 (en) * 2022-01-10 2025-03-27 Gi Innovation, Inc. Pharmaceutical composition for preventing or treating degenerative brain diseases, containing glucagon-like peptide-1 and interleukin-1 receptor antagonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001997A1 (fr) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
JPH08508415A (ja) 1993-12-14 1996-09-10 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 結合組織疾患の全身的遺伝子治療
EP0937082A2 (fr) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathog nes
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO2000047619A1 (fr) 1999-02-10 2000-08-17 Interleukin Genetics, Inc. Therapeutique et diagnostics etablis sur une nouvelle mutation d'il-1b
SI1210320T1 (en) * 1999-07-16 2005-02-28 Leo Pharma A/S Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
CA2383451A1 (fr) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. Analogues d'epirapamycine-28
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
RU2329263C2 (ru) 2000-11-07 2008-07-20 Новартис Аг Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
JP2004536605A (ja) * 2001-07-26 2004-12-09 イーライ・リリー・アンド・カンパニー インターロイキン１β抗体
AU2002324625B2 (en) * 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
ATE556482T1 (de) 2001-12-01 2012-05-15 Iskra Wind Turbines Ltd Synchron-wechselstromgenerator mit einem bremsmechanismus
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
EP2407473A3 (fr) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Procédé de préparation de composés contenant du phosphore
EP1496835A4 (fr) 2002-02-01 2006-10-18 Omeros Corp Compositions et methodes d'inhibition systemique de la degradation du cartilage
BR0307691A (pt) * 2002-02-11 2005-01-11 Arkion Life Sciences Composição, fator de inibição de citocina purificado e seu método de purificação, método de inibição da expressão de citocina e método para modular o sistema imunológico de um animal
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
MXPA05006133A (es) 2002-12-09 2006-03-09 Univ Texas Metodos para inhibir selectivamente la tirosino quinasa jano 3 (jak3).
CA2509136C (fr) 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Antagonistes de l'il-1 beta humaine
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
WO2005047906A1 (fr) 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methodes de controle de l'il-18
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
JP4989456B2 (ja) * 2004-02-26 2012-08-01 ベイラー リサーチ インスティテュート 関節炎の全身処置のための組成物および方法
EP1750746A1 (fr) * 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Procedes d'utilisation d'antagonistes de l'il-1 dans le traitement de maladies auto-inflammatoires
JP2009501128A (ja) 2005-01-20 2009-01-15 ユニバーシティー オブ ロチェスター 炎症疾患および炎症障害の研究および処置のための組成物および方法
EP1866428A2 (fr) 2005-03-18 2007-12-19 Microbia, Inc. Production de caroténoïdes dans de la levure ou des champignons oléagineux
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
JP2009513645A (ja) * 2005-10-26 2009-04-02 ノバルティス アクチエンゲゼルシャフト ＩＬ−１β化合物の新規使用

Also Published As

Publication number Publication date
CA2898369C (fr) 2017-06-20
TWI626056B (zh) 2018-06-11
IL190545A0 (en) 2008-11-03
EP4218815A2 (fr) 2023-08-02
EP3332807A3 (fr) 2018-06-20
LU92326I9 (fr) 2019-01-16
EP2848258B1 (fr) 2017-12-13
NO20200810A1 (no) 2008-07-22
CN101291693A (zh) 2008-10-22
TWI388335B (zh) 2013-03-11
CY2013046I2 (el) 2015-11-04
JO2826B1 (en) 2014-09-15
DK2848258T3 (en) 2018-03-19
BRPI0617830B8 (pt) 2021-05-25
PL1940465T3 (pl) 2013-01-31
TR201802449T4 (tr) 2018-03-21
TNSN08189A1 (en) 2009-10-30
US20180201674A1 (en) 2018-07-19
NO345888B1 (no) 2021-09-27
BRPI0617830A2 (pt) 2011-08-09
HK1121041A1 (en) 2009-04-17
AU2006306280A1 (en) 2007-05-03
IL190545A (en) 2016-09-29
NO20082344L (no) 2008-07-22
PT2848258T (pt) 2018-03-20
US20080286266A1 (en) 2008-11-20
HK1252316A1 (en) 2019-05-24
PH12020500559A1 (en) 2021-06-14
US8409576B2 (en) 2013-04-02
HUE036973T2 (hu) 2018-08-28
IL245387A0 (en) 2016-06-30
LT2848258T (lt) 2018-02-26
IL258983B (en) 2020-10-29
WO2007050607A2 (fr) 2007-05-03
LTC1940465I2 (lt) 2017-12-11
ES2944067T3 (es) 2023-06-19
CY1120018T1 (el) 2018-12-12
KR101749388B1 (ko) 2017-06-20
TWI537003B (zh) 2016-06-11
PL2848258T3 (pl) 2018-06-29
EP1940465B1 (fr) 2012-08-01
US20170218063A1 (en) 2017-08-03
TW201617097A (zh) 2016-05-16
CY2018018I2 (el) 2018-12-12
PH12013501287A1 (en) 2016-02-01
RU2571563C2 (ru) 2015-12-20
SI1940465T1 (sl) 2012-10-30
EP2848258A1 (fr) 2015-03-18
HK1204767A1 (en) 2015-12-04
EP1940465A2 (fr) 2008-07-09
HUS1800025I1 (hu) 2018-07-30
US20120039910A1 (en) 2012-02-16
RU2012133522A (ru) 2014-02-20
TW201302220A (zh) 2013-01-16
PH12013501287B1 (en) 2016-02-01
CN101291693B (zh) 2012-10-03
LU92326I2 (fr) 2014-02-05
LTC2848258I2 (lt) 2019-08-12
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
JOP20140120B1 (ar) 2021-08-17
JP6061747B2 (ja) 2017-01-18
CY2018018I1 (el) 2018-12-12
US20130171167A1 (en) 2013-07-04
RU2008120625A (ru) 2010-01-20
CY2013046I1 (el) 2015-11-04
ES2662420T3 (es) 2018-04-06
EP3332807B1 (fr) 2023-02-22
JP2009513645A (ja) 2009-04-02
ES2389110T3 (es) 2012-10-23
JP2016020377A (ja) 2016-02-04
EP2332577A1 (fr) 2011-06-15
US20150322148A1 (en) 2015-11-12
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
CN102861332A (zh) 2013-01-09
PT1940465E (pt) 2012-10-03
IL245387B (en) 2019-09-26
DK1940465T3 (da) 2012-10-22
BRPI0617830B1 (pt) 2020-10-20
IL258983A (en) 2018-06-28
SI2848258T1 (en) 2018-03-30
EP3332807A2 (fr) 2018-06-13
CA2626214C (fr) 2016-06-21
KR20150013834A (ko) 2015-02-05
CA2898369A1 (fr) 2007-05-03
JP2017206552A (ja) 2017-11-24
KR101518064B1 (ko) 2015-05-06
KR20080059598A (ko) 2008-06-30
IL277406A (en) 2020-11-30
US20210147533A1 (en) 2021-05-20
CA2626214A1 (fr) 2007-05-03
TW200803898A (en) 2008-01-16
JP6286403B2 (ja) 2018-02-28
RU2468817C2 (ru) 2012-12-10
AU2006306280B2 (en) 2010-06-17
US8105587B2 (en) 2012-01-31
EP4218815A3 (fr) 2024-03-27
JP2013166757A (ja) 2013-08-29
LUC00078I2 (fr) 2018-08-14
NZ567222A (en) 2011-07-29
LTPA2018506I1 (lt) 2018-06-25
WO2007050607A3 (fr) 2007-06-28
CA2963828A1 (fr) 2007-05-03
CY1113378T1 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
MA29919B1 (fr) Nouvelle utilisation de composes il-1beta
Ma et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis
Rodrigues et al. Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk
Sélo et al. Allergy to bovine β‐lactoglobulin: specificity of human IgE to tryptic peptides
EA200400849A1 (ru) Композиции смесей для младенцев, содержащие повышенные количества альфа-лактальбумина
Clark et al. Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
EA200801170A1 (ru) Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
DE60231651D1 (de) Proteinreinigungsverfahren
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
DE60235746D1 (de) Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
KR910001057A (ko) 이중특이성 및 올리고특이성 일가 및 올리고가 수용체. 이의 제조방법 및 이의 용도
ATE414106T1 (de) Pegylierte single-domain-antikörper (dab)
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE69530315D1 (de) Rückgewinnung und verwendungen von spezifischen bindungsreagenzen
Yun et al. Modulation of major histocompatibility complex protein expression by human gamma interferon mediated by cysteine proteinase-adhesin polyproteins of Porphyromonas gingivalis
ATE312909T1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
Hughes et al. Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells
Tamamura et al. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains
Geiben-Lynn et al. Noncytolytic inhibition of X4 virus by bulk CD8+ cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by β-chemokines
BE1002375A3 (fr) Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie.
Sakamoto et al. Studies on the interaction between heparin and mouse bone collagenase
CA2629647C (fr) Dosages d'agregation plaquettaire
Dzuris et al. Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules
Giuffre et al. Susceptibilities of simian immunodeficiency virus to protease inhibitors